126 related articles for article (PubMed ID: 17101745)
1. Effect of renal function on the pharmacokinetics of palifermin.
Gillespie B; Zia-Amirhosseini P; Salfi M; Kakkar T; Wang J; Gupta S; Smith B; Robson R; Sullivan JT
J Clin Pharmacol; 2006 Dec; 46(12):1460-8. PubMed ID: 17101745
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers.
Zia-Amirhosseini P; Salfi M; Leese P; Yates W; Danilenko DM; Ring B; Cesano A; Sullivan JT
Clin Pharmacol Ther; 2006 Jun; 79(6):558-69. PubMed ID: 16765144
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
Teichert J; Tuemmers T; Achenbach H; Preiss C; Hermann R; Ruus P; Preiss R
J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis.
Herrero A; Rius Alarcó F; García Díez JM; Mahiques E; Domingo JV
Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):84-7. PubMed ID: 3045024
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
9. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
Radtke ML; Kolesar JM
J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
[TBL] [Abstract][Full Text] [Related]
10. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
Phillips M; Smith W; Balan G; Ward S
J Clin Pharmacol; 2008 Mar; 48(3):279-84. PubMed ID: 18192538
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
[TBL] [Abstract][Full Text] [Related]
13. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF.
Dörr W; Heider K; Spekl K
Int J Radiat Biol; 2005 Aug; 81(8):557-65. PubMed ID: 16298937
[TBL] [Abstract][Full Text] [Related]
14. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.
Gordi T; Blackburn B; Lieu H
J Clin Pharmacol; 2007 Jul; 47(7):825-33. PubMed ID: 17585115
[TBL] [Abstract][Full Text] [Related]
15. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis.
Mistry GC; Majumdar AK; Swan S; Sica D; Fisher A; Xu Y; Hesney M; Xi L; Wagner JA; Deutsch PJ
J Clin Pharmacol; 2006 Oct; 46(10):1128-38. PubMed ID: 16988201
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
[TBL] [Abstract][Full Text] [Related]
18. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
[TBL] [Abstract][Full Text] [Related]
19. Palifermin: new drug. Prevention of oral mucositis: inappropriate evaluation.
Prescrire Int; 2007 Aug; 16(90):135-8. PubMed ID: 17724832
[TBL] [Abstract][Full Text] [Related]
20. Bromfenac disposition in patients with impaired kidney function.
Ermer JC; Boni JP; Cevallos WH; DeCleene S; Burghart P; Rudnick MR; Fruncillo RJ; Berns JS; Cohen RM
Clin Pharmacol Ther; 1997 Mar; 61(3):312-8. PubMed ID: 9084456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
